Vysis prenatal genetic test gains FDA clearance; IPO proceeds to expand marketing efforts.
This article was originally published in The Gray Sheet
VYSIS MARKETING OF ANEUVYSION PRENATAL GENETIC TEST should get a boost from the firm's 3.5 mil. share initial public offering. A portion of the proceeds from the proposed IPO, which is expected to bring in about $44.8 mil., is tabbed for expansion of direct sales and marketing capabilities. Downers Grove, Illinois-based Vysis announced 510(k) clearance of the Aneuvysion assay on Oct. 28; the premarket application was submitted to FDA in June.
You may also be interested in...
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.